Novex Pharma labeling deferrals
This article was originally published in The Tan Sheet
Executive Summary
Canadian private labeler's deferral requests from OTC labeling final rule for Minoxidil Topical Solution 2% (Pharmacia's Rogaine Regular Strength for Men, Rogaine for Women) and Minoxidil Topical Solution 5% For Men (Rogaine Extra Strength for Men) are "appropriate," considering "the time that it has taken to finalize current FDA Drug Facts template labeling," agency says in Feb. 4 correspondence. Letter responds to Novex' Nov. 15 citizen petition. FDA has indicated it will revise the template for the 2% product; no template exists for the 5% version (1"The Tan Sheet" Dec. 10, 2001, p. 3)...
You may also be interested in...
McNeil “Drug Facts” Booklet Pouch Labeling Proposed For Two-Count Sizes
McNeil Consumer Healthcare is requesting a six-month deferral from the OTC labeling final rule requirements to implement "booklet pouch" labeling for two-count sizes of five products
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.